2022 World Conference on Lung Cancer (ePosters)-EP08.02-036. Selpercatinib Striking Response in a Case of Cerebral and Auditory Canal Metastasis of RET Fusion-Positive Non-Small-Cell Lung Cancer

EP08.02-036. Selpercatinib Striking Response in a Case of Cerebral and Auditory Canal Metastasis of RET Fusion-Positive Non-Small-Cell Lung Cancer

Back to course

Pdf Summary

This case study discusses a patient with non-small cell lung cancer (NSCLC) who had metastases to the cerebral and auditory canal. The patient had previously undergone treatment with carbozantinib and pembrolizumab, but experienced progression of the disease. A re-biopsy showed positivity for the RET gene fusion and PDL1 expression of 5%. The patient was then treated with selpercatinib, a selective RET kinase inhibitor, as a fourth-line therapy.<br /><br />The treatment with selpercatinib resulted in a striking response in the patient, with immediate improvement in symptoms related to central nervous system (CNS) involvement. This response was confirmed at three months of treatment through MRI imaging. The efficacy of selpercatinib in patients with CNS involvement has been supported by previous clinical trials.<br /><br />The patient did experience adverse effects from the treatment, including asthenia, nausea, neutropenia, thrombocytopenia, and elevated liver enzyme levels. However, these side effects did not lead to the discontinuation of the treatment.<br /><br />Overall, this case highlights the effectiveness of selpercatinib in treating NSCLC patients with RET gene fusion and CNS involvement. Despite some adverse effects, the treatment resulted in a significant response and improvement in symptoms. This further supports the use of selpercatinib as a targeted therapy for this specific subgroup of patients.

Asset Subtitle

Diana Moreira Sousa

Meta Tag

Speaker Diana Moreira Sousa

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

non-small cell lung cancer

NSCLC

metastases

cerebral

auditory canal

RET gene fusion

selpercatinib

central nervous system

adverse effects

targeted therapy